全文获取类型
收费全文 | 2542篇 |
免费 | 157篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 51篇 |
儿科学 | 67篇 |
妇产科学 | 126篇 |
基础医学 | 292篇 |
口腔科学 | 52篇 |
临床医学 | 232篇 |
内科学 | 614篇 |
皮肤病学 | 126篇 |
神经病学 | 243篇 |
特种医学 | 95篇 |
外科学 | 263篇 |
综合类 | 21篇 |
预防医学 | 192篇 |
眼科学 | 74篇 |
药学 | 113篇 |
中国医学 | 12篇 |
肿瘤学 | 130篇 |
出版年
2023年 | 17篇 |
2022年 | 32篇 |
2021年 | 86篇 |
2020年 | 40篇 |
2019年 | 74篇 |
2018年 | 90篇 |
2017年 | 55篇 |
2016年 | 52篇 |
2015年 | 77篇 |
2014年 | 87篇 |
2013年 | 92篇 |
2012年 | 121篇 |
2011年 | 142篇 |
2010年 | 76篇 |
2009年 | 88篇 |
2008年 | 129篇 |
2007年 | 149篇 |
2006年 | 131篇 |
2005年 | 109篇 |
2004年 | 109篇 |
2003年 | 100篇 |
2002年 | 82篇 |
2001年 | 86篇 |
2000年 | 85篇 |
1999年 | 98篇 |
1998年 | 18篇 |
1997年 | 24篇 |
1995年 | 17篇 |
1994年 | 9篇 |
1992年 | 33篇 |
1991年 | 32篇 |
1990年 | 36篇 |
1989年 | 42篇 |
1988年 | 26篇 |
1987年 | 22篇 |
1986年 | 20篇 |
1985年 | 20篇 |
1984年 | 21篇 |
1983年 | 17篇 |
1982年 | 9篇 |
1981年 | 9篇 |
1979年 | 8篇 |
1978年 | 13篇 |
1976年 | 14篇 |
1975年 | 9篇 |
1974年 | 8篇 |
1973年 | 8篇 |
1970年 | 9篇 |
1969年 | 7篇 |
1968年 | 7篇 |
排序方式: 共有2703条查询结果,搜索用时 15 毫秒
1.
2.
3.
Development of grating acuity in infants with regressed stage 3 retinopathy of prematurity 总被引:4,自引:0,他引:4
The acuity card procedure was used to measure grating acuity in 17 infants with regressed Stage 3 retinopathy of prematurity (ROP) who had no lasting anatomic changes in the retina or optic nerve. Results were compared with those of 28 healthy preterm infants and 28 infants matched by birth weight and gestational age who did not have Stage 3 ROP. Infants in the ROP group showed delayed grating acuity development until 2 years of age. This difference among groups was significant at the 3-5- and 10-12-month test ages but not at the 0-1-, 8-9-, and 16-18-month test ages. Post hoc analyses indicated that the delay in acuity development shown by the ROP group was due to the poor acuity scores of the infants in that group who had central nervous system abnormalities of periventricular leukomalacia or severe (Grade III or IV) intraventricular hemorrhage. When the data of these infants were removed from the analysis, the ROP group showed acuity development similar to that of both the healthy preterm group and the group of infants with matched birth weights and gestational ages who did not have Stage 3 ROP. 相似文献
4.
5.
O Blin G Masson J P Azulay J Fondarai G Serratrice 《British journal of clinical pharmacology》1990,30(5):769-773
Yawning and spontaneous blink rate (SBR) are two physiological reflexes which have been incompletely examined but one neurobiological step of these two behaviours seems, at least in part, dopamine-dependent. The reference dopaminergic agonist, apomorphine hydrochloride (0.5, 1, and 2 micrograms kg-1 s.c.), was compared with a placebo in a double-blind latin-square design, and was shown to induce yawning and increase SBR in a population of eight healthy volunteers. These two behavioral effects were not dose-related. The individual SBR differences were correlated with the individual number of yawns for all the four treatments at the 10-30 min interval. Thus, parallel yawning and SBR behaviour suggests a similar pharmacological mechanism. Apomorphine-induced yawning and blinking may be therefore of use in the evaluation of central dopaminergic pathways in man. 相似文献
6.
Beatriz Luna Sara K Doll Stephen J Hegedus Nancy J Minshew John A Sweeney 《Neuropsychopharmacology》2007,61(4):474-481
BACKGROUND: Executive dysfunction has been reported at different ages in autism. It is not clear however, when this impairment emerges or how its expression is affected by development. METHODS: 61 non-mentally retarded autism participants (AUT) and 61 age, gender, and IQ matched typically developing participants (CON) were assessed with two oculomotor executive function tasks, the oculomotor delayed response task (ODR) and the antisaccade task (AS), as well as a visually-guided saccade sensorimotor task (VGS). RESULTS: The AUT group demonstrated impairments in response inhibition and spatial working memory at all ages tested. Developmental improvements in speed of sensorimotor processing and voluntary response inhibition were similar in both groups indicating sparing of some attentional control of behavior. Developmental progression in the speed of initiating a cognitive plan and maintaining information on line over time, however, was impaired in the AUT group indicating abnormal development of working memory. CONCLUSIONS: These results indicate that while executive dysfunction is present throughout development, there is evidence for both typical and atypical developmental progression of executive functions in autism. The plasticity suggested by the developmental improvements may have implications regarding appropriate developmental epochs and types of interventions aimed at enhancing cognitive capacities in individuals with autism. 相似文献
7.
8.
Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. 总被引:6,自引:2,他引:4
下载免费PDF全文
![点击此处可从《The American journal of pathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
A. K. El-Naggar S. Lai G. Clayman J. K. Lee M. A. Luna H. Goepfert J. G. Batsakis 《The American journal of pathology》1997,151(6):1767-1774
We studied 11 head and neck squamous carcinoma (HNSC) cell lines and 46 primary tumors for p16 gene status by protein, mRNA, and DNA genetic/epigenetic analyses to determine the incidence, the mechanism(s), and the potential biological significance of its inactivation. Of the 11 cell lines, only 1 showed intact p16 and 10 lacked its protein and mRNA; DNA analysis of these 10 cell lines showed 2 homozygous deletions, 6 methylations at exon 1 and 2, and 2 with no detectable abnormalities. In primary tumors, 16 (34.7%) of the 46 showed detectable p16 protein and mRNA; of these, 12 had no DNA abnormalities and 4 had only exon 2 methylation. Loss of p16 expression was found in three tumors with concurrent mutation at exon 2 and methylation at exon 2 (two) and both 1 and 2 (one). Of the 30 tumors that lacked p16 protein, 27 also lacked mRNA, 1 had detectable p16 mRNA, and 2 failed RT-PCR amplification. Twenty-two of the thirty tumors showed DNA alterations and eight manifested no abnormalities; DNA alterations comprised 6 homozygous deletions, 2 concurrent mutations and methylation of exon 2, and 13 with methylation at exon 1 and exons 1 and 2 (12 with methylation only and 1 with mutation) at exon 1. Except for patients' gender (P = 0.02), no significant correlation between p16 and clinicopathological factors was observed. We conclude that in HNSC 1) intragenic p16 alterations are infrequent events, 2) methylation of exon 1 constitutes a common mechanism in silencing the p16 gene, 3) p16 inactivation may play an important role in the early development and progression of HNSC, and 4) no association between p16 alterations and conventional clinicopathological factors was noted in this cohort. 相似文献
9.
Salivary dermal analogue tumors arising in lymph nodes 总被引:3,自引:0,他引:3
Dermal analogue tumor, an unusual type of monomorphic salivary adenoma, occurs in the parotid gland and rarely in other salivary tissues. This report describes three patients with dermal analogue tumors arising from ectopic salivary tissue in lymph nodes. Two tumors appeared in the periparotid lymph nodes and one in the lateral upper cervical region. All of the patients were men, aged 50 to 60 years, who all had a painless neck mass for 1 year or longer. Currently, the patients are free of disease 14, 3, and 2 years, respectively, after surgical excision. Dermal analogue monomorphic adenomas join several other salivary tumors in possible intranodal origin and should not be confused with metastases. 相似文献
10.
Studies on the mechanism of 3-deazaguanine cytotoxicity in L1210-sensitive and -resistant cell lines
Summary 3-Deazaguanine (3-DG), a purine analogue, has unusual antitumor activity against experimental mammary tumor models and a number of other solid tumors. Others have shown that mutant CHO cells deficient in hypoxanthine guanine phosphoribosyl transferase (HGPRTase) or adenine phosphoribosyl transferase (APRTase) are resistant to 3-DG. We developed a L1210 cell line resistant to 3-DG, L1210/3-DG, by subculturing the parent L1210/0 cells in the presence of increasing concentrations of 3-DG. The IC50 was 3.5 M and 620 M for L1210/0 and L1210/3-DG, respectively. Cytotoxicity studies proved the resistance to be stable. Examination of the baseline-specific activity of HGPRTase and APRTase showed that the former was 118-fold lower in L1210/3-DG than in L1210/0, and the latter demonstrated no difference. A 4-h treatment of the cell lines at IC50 doses showed 48% and 23% reductions in IMP dehydrogenase in L1210/0 and L1210/3-DG, respectively. The rate of de novo purine biosynthesis was studied by using [14C]formic acid. Formate flux increased 2-fold in L1210/3DG in concert with the observed deficiency of HGPRTase in the cell line. 3-DG uptake was studied with [14C]-labelled compound. The total radioactivity was 9-fold higher in L1210/0 than in L1210/3-DG at 2 h. Subsequent chromatographic separation of radioactivity showed the 3-DG and 3-deazaguanosine pools of the drug to be equal in both lines. However, 3-DG nucleotide pools at 1 min and 2 h were 2.5-fold and 16-fold lower, respectively, in L1210/3-DG than in L1210/0. 3-DG incorporation studies with radiolabelled drug demonstrated that 3-deazaguanine is incorporated in the acid-insoluble fraction of the cell. These studies conclude that HGPRTase, and not APRTase, is required for the activation of drug. Inhibition of IMP dehydrogenase is partially responsible for antitumor activity of the drug. The incorporation of drug into nucleic acids may be a major mechanism for its antitumor activity. Further studies using a cloned cDNA probe for hypoxanthine guanine phosphoribosyltransferase (HGPRT) demonstrated no change in the DNA arrangements of the L1210/3-DG cell line, and Northern blot analysis showed approximately equal expression of mRNA in both cell lines.Abbreviations used APRTase
adenine phosphoribosyltransferase
- HGPRTase
Hypoxanthine guanine phosphoribosyltransferase
- IMPD
Inosine mono-phosphate dehydrogenase
- PRPP
5-Phosphorylribose-1-pyrophosphate
- AOPCP
, -Methyleneadenosine 5-diphosphate
- NAD
Nicotineamide dinucleotide
- EDTA
Ethylenediamine tetra acetic acid
Presented at annual meeting of American Association of Cancer Research in May, 1986Supported in part by Warner-Lambert Company, Ann Arbor, Michigan 相似文献